English
Back
Open Account
INNOCARE
wrote a column · May 28 09:41

People's Daily runs consecutive reports on InnoCare Pharma: China's innovative drugs achieve leapfrog development

People's Daily highlighted the development of innovative drugs, with InnoCare Pharma repeatedly featured as a representative example.
People's Daily highlights the development of innovative drugs, with InnoCare Pharma's practices featured repeatedly as a model case. According to People's Daily: 'Safety and efficacy are the lifeblood of innovative drugs.' In December 2025, Beijing-based InnoCare Pharma Co., Ltd. received conditional approval from China’s National Medical Products Administration (NMPA) through its priority review pathway for Zoletritinib Tablets, a Class 1 innovative drug, offering new treatment options for patients with lung cancer, brain metastases, and thyroid cancer. A company spokesperson stated,The company has established a high-quality management system covering the entire process, strictly upholding the safety baseline for pharmaceuticals and striving to ensure that every innovative drug is safe, effective, and compliant with quality standards. People's Daily reported:“In 2025, we completed two out-licensing deals and obtained approval for a new innovative drug, resulting in our first-ever positive net cash flow from operating activities.”A spokesperson for InnoCare Pharma Co., Ltd. (hereinafter referred to as 'InnoCare') explained that, as a previously unprofitable technology-focused listed company, InnoCare was included in the newly established Sci-Tech Innovation Growth Tier. Long-term capital market support for 'hardcore tech' has enabled the company to enter a phase of harvesting returns on its R&D investments, gradually converting innovation expenditures into tangible outcomes and successfully removing the 'U' designation indicating unprofitability. Initial results of the reform are becoming evident.Including InnoCare, six companies have achieved profitability for the first time.Became among the first 'graduates' of the Sci-Tech Innovation Growth Tier. The 40 companies in this tier reported a 37.2% year-over-year increase in revenue last year, leading the entire market in growth rate.
According to People's Daily: Safety and efficacy are the lifeblood of innovative drugs. In December 2025, Beijing-based InnoCare Pharma Co., Ltd. received conditional approval from China’s National Medical Products Administration (NMPA) through its priority review and approval pathway for Zolecitinib Tablets, a Class 1 innovative drug, offering new treatment options for patients with lung cancer, brain metastases, and thyroid cancer. A company representative stated,The company has established a high-quality management system covering the entire process, strictly upholding the baseline of drug safety and striving to ensure that every innovative drug is safe, effective, and compliant with quality standards.
People's Daily highlights the development of innovative drugs, with InnoCare Pharma's practices featured repeatedly as a model case. According to People's Daily: 'Safety and efficacy are the lifeblood of innovative drugs.' In December 2025, Beijing-based InnoCare Pharma Co., Ltd. received conditional approval from China’s National Medical Products Administration (NMPA) through its priority review pathway for Zoletritinib Tablets, a Class 1 innovative drug, offering new treatment options for patients with lung cancer, brain metastases, and thyroid cancer. A company spokesperson stated,The company has established a high-quality management system covering the entire process, strictly upholding the safety baseline for pharmaceuticals and striving to ensure that every innovative drug is safe, effective, and compliant with quality standards. People's Daily reported:“In 2025, we completed two out-licensing deals and obtained approval for a new innovative drug, resulting in our first-ever positive net cash flow from operating activities.”A spokesperson for InnoCare Pharma Co., Ltd. (hereinafter referred to as 'InnoCare') explained that, as a previously unprofitable technology-focused listed company, InnoCare was included in the newly established Sci-Tech Innovation Growth Tier. Long-term capital market support for 'hardcore tech' has enabled the company to enter a phase of harvesting returns on its R&D investments, gradually converting innovation expenditures into tangible outcomes and successfully removing the 'U' designation indicating unprofitability. Initial results of the reform are becoming evident.Including InnoCare, six companies have achieved profitability for the first time.Became among the first 'graduates' of the Sci-Tech Innovation Growth Tier. The 40 companies in this tier reported a 37.2% year-over-year increase in revenue last year, leading the entire market in growth rate.
People's Daily reported:“In 2025, we completed two out-licensing deals and secured approval for a new innovative drug, resulting in positive net cash flow from operating activities for the first time.”A representative of InnoCare Pharma Co., Ltd. (hereinafter referred to as 'InnoCare') explained that as an unprofitable technology-focused listed company prior to profitability, the firm was included in the newly established Sci-Tech Innovation Growth Tier. Long-term capital market support for 'hard tech' has enabled the company to enter a phase of harvesting returns on innovation, gradually monetizing its R&D investments and successfully removing the 'U' designation to graduate from the tier.
The reform is already showing initial results.Including InnoCare, six companies achieved profitability for the first time,Became among the first 'graduates' of the Sci-Tech Innovation Growth Tier. The 40 companies in this tier reported a 37.2% year-over-year increase in revenue last year, leading the entire market in growth rate.
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
16K Views
Report
Comments
Write a Comment...